BI
NGM

BVF Inc’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

BVF Inc’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-955,000
Closed -$14.6M – 84
2022
Q1 		$14.6M Hold
955,000
– – 0.58% 46
2021
Q4 		$16.9M Hold
955,000
– – 0.61% 43
2021
Q3 		$20.1M Hold
955,000
– – 0.78% 38
2021
Q2 		$18.8M Buy
+955,000
New +$22.4M 0.71% 39

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc's NGM Position: Q2 2022 in Review

BVF Inc sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2022, closing a stake of 955,000 shares — an estimated $14.6M sold.

BVF Inc first reported a position in NGM in Q2 2021 and held it in 4 quarters. The position peaked at $20.1M in Q3 2021. 123 funds tracked by Wall St. Rank hold NGM as of Q2 2022.

  • BVF Inc reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • BVF Inc sold 955,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $14.6M.
  • BVF Inc first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • BVF Inc's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $20.1M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on BVF Inc's 13F filing for Q2 2022, filed 15 Aug 2022.